You are here: Home » Companies » News
Business Standard

Glenmark Pharma inks exclusive licensing agreement with Lotus International

Glenmark Pharmaceuticals Ltd on Thursday said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd

Glenmark Pharmaceuticals | Companies

Press Trust of India  |  New Delhi 

Glenmark Pharmaceuticals

Ltd on Thursday said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd for commercializing its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.

Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for manufacturing and supply of Ryaltris.

On the other hand Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.

Glenmark will receive an upfront payment as well as regulatory and sales-based milestone payments from Lotus, it added.

"This partnership will provide patients access to a highly effective and proven treatment for allergic rhinitis in these key South-East Asian markets," Ltd Chief Commercial Officer Robert Crockart said.

Lotus CEO, Petar Vazharov said, "the partnership not only strengthens the competitiveness of our overall product portfolio but also accelerates our expansion in key SEA countries."

He further said this is also the first brand product to be included in Lotus' respiratory portfolio with strong clinical data and IP protection.

Ryaltris, developed by Glenmark, is a novel, fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis in adults and pediatric patients, 12 years of age and older.

Glenmark said it has also entered into commercial agreements with several partners around the world, including Menarini for the commercialization of Ryaltris in select EU markets, with Bausch Health in Canada (where it is under review by Health Canada), with Grand Pharma in China and with Yuhan Corporation in South Korea for commercialization of the nasal spray.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, January 20 2022. 10:55 IST